Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).

Date publication

novembre 2018

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe , Dr PREVOST Alain

Tous les auteurs :
Roché H, Eymard JC, Radji A, Prevost A, Diab R, Lamuraglia M, Soumoudronga RF, Gasnereau I, Toledano A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30445935

Résumé

The ZOHé study was a prospective, non-interventional, multicentre study in France to assess the use of biosimilar filgrastim Zarzio® (Sandoz filgrastim) in routine clinical practice in patients at risk of neutropenia-inducing chemotherapy (CT).

Mots clés

Biosimilar pharmaceuticals, Chemotherapy, Febrile neutropenia, Filgrastim, Guidelines recommendations, Observational study, Real-world, Solid tumours

Référence

BMC Cancer. 2018 Nov 16;18(1):1127